ALGS (STOCKS)
Aligos Therapeutics, Inc. Common Stock
$7.470000
+0.290000 (+4.04%)
Prev close: $7.180000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Lawrence M. Blatt
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $45.84M
- Employees
- 70
- P/E (TTM)
- -0.38
- P/B (TTM)
- 0.64
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-3.04 | $-1.94 | -1.1020 | -56.86% |
|
Jun 2025 (Q2)
|
$-1.53 | $-2.41 | +0.8806 | +36.53% |
|
Mar 2025 (Q1)
|
$-2.11 | $-2.85 | +0.7426 | +26.03% |
|
Dec 2024 (Q4)
|
$-3.40 | $-2.55 | -0.8534 | -33.51% |
Financial Statements
| Revenues | $2.62M |
| Benefits Costs and Expenses | $88.77M |
| Costs And Expenses | $88.77M |
| Operating Expenses | $89.38M |
| Research and Development | $68.45M |
| Other Operating Expenses | $20.93M |
| Operating Income/Loss | -$86.73M |
| Income/Loss From Continuing Operations After Tax | -$86.46M |
| Income/Loss From Continuing Operations Before Tax | -$86.15M |
| Income Tax Expense/Benefit | $311.00K |
| Interest Income/Expense After Provision For Losses | $1.90M |
| Interest Income/Expense Operating, Net | $1.90M |
| Net Income/Loss | -$86.46M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$86.46M |
| Net Income/Loss Available To Common Stockholders, Basic | -$86.46M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$12.55 |
| Diluted Earnings Per Share | -$19.78 |
| Basic Average Shares | 29,135,042 |
| Diluted Average Shares | 29,436,254 |
| Assets | $109.76M |
| Current Assets | $103.44M |
| Cash | $99.10M |
| Other Current Assets | $4.34M |
| Noncurrent Assets | $6.33M |
| Fixed Assets | $2.04M |
| Other Non-current Assets | $4.29M |
| Liabilities | $37.93M |
| Current Liabilities | $21.99M |
| Accounts Payable | $4.65M |
| Wages | $5.28M |
| Other Current Liabilities | $12.06M |
| Noncurrent Liabilities | $15.94M |
| Equity | $71.83M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $71.83M |
| Liabilities And Equity | $109.76M |
| Net Cash Flow From Operating Activities | -$79.16M |
| Net Cash Flow From Operating Activities, Continuing | -$79.16M |
| Net Cash Flow From Investing Activities | -$15.83M |
| Net Cash Flow From Investing Activities, Continuing | -$15.83M |
| Net Cash Flow From Financing Activities | $101.61M |
| Net Cash Flow From Financing Activities, Continuing | $101.61M |
| Net Cash Flow | $6.62M |
| Net Cash Flow, Continuing | $6.62M |
| Comprehensive Income/Loss | -$86.55M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$86.58M |
| Other Comprehensive Income/Loss | -$113.78M |
| Other Comprehensive Income/Loss Attributable To Parent | -$122.00K |